Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW 1,609.00
+10.00 (0.63%)
At close: Dec 5, 2025
Xcell Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 1,362 | 1,934 | 1,124 | 1,020 | 1,966 | 540.2 | Upgrade
|
| Other Revenue | - | - | - | 0 | - | - | Upgrade
|
| Revenue | 1,362 | 1,934 | 1,124 | 1,020 | 1,966 | 540.2 | Upgrade
|
| Revenue Growth (YoY) | -29.97% | 72.11% | 10.18% | -48.12% | 264.00% | 531.11% | Upgrade
|
| Cost of Revenue | 2,874 | 3,333 | 2,987 | 2,773 | 2,284 | 1,641 | Upgrade
|
| Gross Profit | -1,512 | -1,399 | -1,863 | -1,753 | -318.08 | -1,101 | Upgrade
|
| Selling, General & Admin | 5,100 | 4,323 | 3,400 | 3,219 | 3,058 | 1,819 | Upgrade
|
| Research & Development | 2,417 | 2,728 | 2,753 | 2,596 | 1,832 | 1,166 | Upgrade
|
| Amortization of Goodwill & Intangibles | 103.56 | 53.23 | 53.83 | 73.48 | 56.2 | 39.27 | Upgrade
|
| Other Operating Expenses | 28.56 | 36.01 | 71.45 | 140.21 | 78.1 | 4.63 | Upgrade
|
| Operating Expenses | 8,583 | 7,931 | 7,076 | 6,546 | 5,387 | 3,376 | Upgrade
|
| Operating Income | -10,095 | -9,330 | -8,939 | -8,299 | -5,705 | -4,477 | Upgrade
|
| Interest Expense | - | -4.4 | -3.12 | -2.89 | -179.78 | -827.41 | Upgrade
|
| Interest & Investment Income | 242.13 | 201.29 | 50.84 | 114.02 | 41.75 | 15.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 5.72 | 12.84 | 2.52 | 11.57 | 2.38 | -0.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -256.34 | -295.6 | -257.58 | -165.59 | -3,186 | -4,838 | Upgrade
|
| EBT Excluding Unusual Items | -10,104 | -9,416 | -9,147 | -8,342 | -9,026 | -10,127 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.43 | 2.72 | -0.87 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 85.09 | -130.13 | 21 | -0.53 | -12 | 3 | Upgrade
|
| Asset Writedown | - | - | -154.12 | - | - | - | Upgrade
|
| Pretax Income | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 | Upgrade
|
| Net Income | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 | Upgrade
|
| Net Income to Common | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 10 | 9 | 9 | 8 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 10 | 9 | 9 | 8 | 2 | Upgrade
|
| Shares Change (YoY) | 14.66% | 13.14% | 1.02% | 5.71% | 364.87% | 3.12% | Upgrade
|
| EPS (Basic) | -914.66 | -953.76 | -1049.40 | -952.90 | -1091.40 | -5683.16 | Upgrade
|
| EPS (Diluted) | -914.88 | -954.00 | -1049.40 | -953.00 | -1091.40 | -5683.16 | Upgrade
|
| Free Cash Flow | -9,273 | -7,379 | -7,008 | -8,475 | -5,952 | -5,657 | Upgrade
|
| Free Cash Flow Per Share | -847.37 | -737.48 | -792.48 | -968.02 | -718.67 | -3175.38 | Upgrade
|
| Gross Margin | -110.99% | -72.30% | -165.77% | -171.89% | -16.18% | -203.76% | Upgrade
|
| Operating Margin | -741.13% | -482.33% | -795.37% | -813.59% | -290.14% | -828.78% | Upgrade
|
| Profit Margin | -734.84% | -493.36% | -825.74% | -817.85% | -459.67% | -1874.20% | Upgrade
|
| Free Cash Flow Margin | -680.78% | -381.48% | -623.58% | -830.82% | -302.69% | -1047.18% | Upgrade
|
| EBITDA | -8,385 | -7,677 | -7,341 | -6,786 | -4,686 | -3,795 | Upgrade
|
| EBITDA Margin | - | - | - | - | -238.34% | - | Upgrade
|
| D&A For EBITDA | 1,710 | 1,653 | 1,598 | 1,513 | 1,019 | 681.79 | Upgrade
|
| EBIT | -10,095 | -9,330 | -8,939 | -8,299 | -5,705 | -4,477 | Upgrade
|
| EBIT Margin | - | - | - | - | -290.14% | - | Upgrade
|
| Advertising Expenses | - | 154.72 | 315.24 | 267.87 | 279.25 | 97.97 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.